Nuveen Asset Management LLC trimmed its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 0.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,348 shares of the pharmaceutical company’s stock after selling 108 shares during the period. Nuveen Asset Management LLC’s holdings in Vertex Pharmaceuticals were worth $2,543,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Parallel Advisors LLC grew its stake in Vertex Pharmaceuticals by 5.8% in the 4th quarter. Parallel Advisors LLC now owns 1,091 shares of the pharmaceutical company’s stock worth $180,000 after acquiring an additional 60 shares during the period. Kovack Advisors Inc. raised its stake in Vertex Pharmaceuticals by 4.2% during the fourth quarter. Kovack Advisors Inc. now owns 1,484 shares of the pharmaceutical company’s stock worth $246,000 after acquiring an additional 60 shares during the period. Grandfield & Dodd LLC raised its stake in Vertex Pharmaceuticals by 1.0% during the fourth quarter. Grandfield & Dodd LLC now owns 6,239 shares of the pharmaceutical company’s stock worth $1,034,000 after acquiring an additional 61 shares during the period. ETRADE Capital Management LLC raised its stake in Vertex Pharmaceuticals by 0.5% during the fourth quarter. ETRADE Capital Management LLC now owns 11,897 shares of the pharmaceutical company’s stock worth $1,972,000 after acquiring an additional 65 shares during the period. Finally, Brown Advisory Inc. raised its stake in Vertex Pharmaceuticals by 1.1% during the fourth quarter. Brown Advisory Inc. now owns 6,401 shares of the pharmaceutical company’s stock worth $1,061,000 after acquiring an additional 69 shares during the period. Institutional investors own 95.23% of the company’s stock.

In other news, SVP Paul M. Silva sold 2,812 shares of the stock in a transaction on Tuesday, February 19th. The shares were sold at an average price of $186.97, for a total transaction of $525,759.64. Following the transaction, the senior vice president now owns 18,903 shares in the company, valued at approximately $3,534,293.91. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP David Altshuler sold 5,624 shares of the stock in a transaction on Tuesday, February 19th. The stock was sold at an average price of $187.00, for a total transaction of $1,051,688.00. Following the transaction, the executive vice president now owns 32,604 shares in the company, valued at approximately $6,096,948. The disclosure for this sale can be found here. In the last quarter, insiders sold 214,999 shares of company stock valued at $39,289,000. Insiders own 0.75% of the company’s stock.

Several research firms recently weighed in on VRTX. BidaskClub lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Zacks Investment Research cut shares of Vertex Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Friday, March 8th. Svb Leerink reiterated a “market perform” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, March 19th. William Blair upgraded shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $183.85 price objective for the company in a report on Tuesday. Finally, Cowen reiterated a “buy” rating and issued a $220.00 price objective on shares of Vertex Pharmaceuticals in a report on Wednesday, March 6th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. Vertex Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $204.44.

VRTX stock opened at $185.82 on Thursday. The company has a market cap of $47.51 billion, a P/E ratio of 65.66, a price-to-earnings-growth ratio of 2.78 and a beta of 1.65. Vertex Pharmaceuticals Incorporated has a 12 month low of $144.07 and a 12 month high of $195.81.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Tuesday, February 5th. The pharmaceutical company reported $1.30 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.06 by $0.24. The business had revenue of $870.11 million during the quarter, compared to the consensus estimate of $818.29 million. Vertex Pharmaceuticals had a net margin of 68.81% and a return on equity of 24.15%. The firm’s quarterly revenue was up 33.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.61 EPS. Equities analysts predict that Vertex Pharmaceuticals Incorporated will post 3.04 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Nuveen Asset Management LLC Trims Stake in Vertex Pharmaceuticals Incorporated (VRTX)” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.watchlistnews.com/nuveen-asset-management-llc-trims-stake-in-vertex-pharmaceuticals-incorporated-vrtx/2924148.html.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.

Featured Article: Net Margin – Understanding the Different Kinds of Profit

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.